Viking Therapeutics, Inc. Stock Analysis & AI Score
Viking Therapeutics, Inc. (VKTX) has an ST Score of 49.7 (C+), driven by its Sentiment (A+) and held back by its Profitability (F). Analysts rate it Buy with a $98.20 price target (+167.2% upside).
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
ST Score
Viking Therapeutics, Inc. (VKTX) has an ST Score of 49.7 (C+), driven by its Sentiment (A+) and held back by its Profitability (F). Analysts rate it Buy with a $98.20 price target (+167.2% upside).
- Strongest
- SentimentA+
- Weakest
- ProfitabilityF
All factor grades
- SentimentA+
- MomentumA
- ForecastA
- ValuationB-
- Financial StrengthB-
- GrowthD-
- ProfitabilityF
- Piotroski1/9
Contact
VKTX stock: frequently asked questions
What is VKTX's ST Score?
Viking Therapeutics, Inc. (VKTX) has an ST Score of 49.7 (C+), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is VKTX a buy, hold, or sell?
Analysts rate VKTX a Buy, with a price target of $98.20 (+167.2% vs the current price). Our ST Score grades it C+ (49.7/100). The ST Score is a data-driven signal, not a recommendation.
What are VKTX's factor grades?
Valuation B-, Profitability F, Financial Strength B-, Momentum A, Growth D-, Forecast A, Sentiment A+.
What is VKTX's valuation grade?
Viking Therapeutics, Inc. (VKTX) earns a valuation grade of B-, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is VKTX's growth grade?
Viking Therapeutics, Inc. (VKTX) earns a growth grade of D-, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is VKTX's profitability grade?
Viking Therapeutics, Inc. (VKTX) earns a profitability grade of F, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is VKTX's financial strength grade?
Viking Therapeutics, Inc. (VKTX) earns a financial strength grade of B-, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for VKTX?
The average analyst price target for Viking Therapeutics, Inc. (VKTX) is $98.20 from 24 analysts, which is +167.2% versus the recent price of $36.75.
What is VKTX's Piotroski score?
Viking Therapeutics, Inc. (VKTX) has a Piotroski F-Score of 1 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.